Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its patented drug candidate Lucid-MS toward Phase 2 clinical trials for multiple sclerosis (MS), marking a potential shift in treatment approaches for the neurodegenerative disease. Unlike existing MS therapies that primarily target the immune system, Lucid-MS is a nonimmunomodulatory, neuroprotective compound designed to directly prevent degradation of the myelin sheath, the protective layer around nerve fibers that is damaged in MS. The company recently filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration and is preparing for a Phase 2 trial following successful completion of Phase 1 safety studies and key toxicology programs, according to an editorial published by AINewsWire.
The editorial highlights over a decade of preclinical research supporting Lucid-MS, including studies in animal models that demonstrated preservation of myelin integrity, reduced degradation, and improved functional recovery. This research underscores the potential of Lucid-MS to address the underlying pathology of MS rather than just managing symptoms or modulating immune responses. Quantum BioPharma is also collaborating with Massachusetts General Hospital on validating a novel PET imaging technique designed to directly measure myelin integrity in MS patients. This tool could be critical for evaluating the effectiveness of remyelinating therapies like Lucid-MS in clinical trials and future practice.
Recent clinical and regulatory developments from major pharmaceutical companies, including Novartis AG (NYSE: NVS), Merck & Co. Inc. (NYSE: MRK), TG Therapeutics Inc. (NASDAQ: TGTX), and Bristol Myers Squibb Company (NYSE: BMY), underscore continued innovation across autoimmune, immune-mediated, and chronic inflammatory disease treatment markets. These advancements highlight the growing interest in novel therapies that go beyond immunosuppression to directly repair or protect neural structures.
Quantum BioPharma is a biopharmaceutical company focused on building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is developing Lucid-MS as a first-in-class drug candidate. The company also retains a 19.84% stake in Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), which markets the OTC product UNBUZZD(TM), and receives royalty payments from its sales. Additional information about Quantum BioPharma is available in the company’s newsroom at https://ibn.fm/QNTM.
